Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ina A Eilertsen

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
International Journal of Cancer|November 18, 2018
Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic propertiesPeter W Eide, Ina A Eilertsen, Anita Sveen, et al.
International Journal of Cancer|August 20, 2018
Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancerIna A Eilertsen, Anita Sveen, Jonas M Strømme, et al.
Cancer Letters|November 4, 2019
Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancerIna A Eilertsen, Seyed H Moosavi, Jonas M Strømme, et al.
Molecular Oncology|May 31, 2017
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumorsMatthias Kolberg, Jarle Bruun, Astrid Murumägi, et al.
ESMO Open|July 20, 2019
Exploratory analyses of consensus molecular subtype-dependent associations of <i>TP53</i> mutations with immunomodulation and prognosis in colorectal cancerJørgen Smeby, Anita Sveen, Christian H Bergsland, et al.
Cellular Signalling|September 15, 2012
NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathwayPeter W Eide, Lina Cekaite, Stine A Danielsen, et al.
Ebiomedicine|August 18, 2020
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activityJørgen Smeby, Kushtrim Kryeziu, Kaja C G Berg, et al.
Oncogenesis|January 27, 2026
Common gene mutations in 103 authenticated colorectal cancer cell linesChristian Kranjec, Ina A Eilertsen, Luís Nunes, et al.
NPJ Genomic Medicine|July 15, 2021
Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancerPeter W Eide, Seyed H Moosavi, Ina A Eilertsen, et al.
Oncogenesis|May 17, 2019
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancerJørgen Smeby, Anita Sveen, Ina A Eilertsen, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
International Journal of Cancer|November 18, 2018
Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic propertiesPeter W Eide, Ina A Eilertsen, Anita Sveen, et al.
International Journal of Cancer|August 20, 2018
Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancerIna A Eilertsen, Anita Sveen, Jonas M Strømme, et al.
Cancer Letters|November 4, 2019
Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancerIna A Eilertsen, Seyed H Moosavi, Jonas M Strømme, et al.
Molecular Oncology|May 31, 2017
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumorsMatthias Kolberg, Jarle Bruun, Astrid Murumägi, et al.
ESMO Open|July 20, 2019
Exploratory analyses of consensus molecular subtype-dependent associations of <i>TP53</i> mutations with immunomodulation and prognosis in colorectal cancerJørgen Smeby, Anita Sveen, Christian H Bergsland, et al.
Cellular Signalling|September 15, 2012
NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathwayPeter W Eide, Lina Cekaite, Stine A Danielsen, et al.
Ebiomedicine|August 18, 2020
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activityJørgen Smeby, Kushtrim Kryeziu, Kaja C G Berg, et al.
Oncogenesis|January 27, 2026
Common gene mutations in 103 authenticated colorectal cancer cell linesChristian Kranjec, Ina A Eilertsen, Luís Nunes, et al.
NPJ Genomic Medicine|July 15, 2021
Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancerPeter W Eide, Seyed H Moosavi, Ina A Eilertsen, et al.
Oncogenesis|May 17, 2019
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancerJørgen Smeby, Anita Sveen, Ina A Eilertsen, et al.
Pageof 3